Literature DB >> 2015169

The effects of flosequinan on regional blood flow in normal man.

R A Scott1, K L Woods, D B Barnett.   

Abstract

1. The effects of 100 mg and 200 mg flosequinan on limb, hepatic and renal blood flow were investigated in 14 healthy male volunteers in a placebo controlled double-blind randomised three-way crossover study. 2. Heart rate, blood pressure, forearm blood flow and venous capacitance measured by volume plethysmography, were recorded sequentially over 4 h, after oral dosing. 3. Apparent hepatic and renal blood flows were estimated 2 h post-dose by indocyanine green dye clearance and clearance of 125-iodohippuran respectively. 4. Flosequinan produced dose-dependent reductions in resting diastolic blood pressure, accompanied by a rise in heart rate. 5. Forearm blood flow increased to a maximum 4 h after 200 mg and this was accompanied by a fall in forearm vascular resistance. 6. Hepatic blood flow increased, compared with placebo, after 200 mg flosequinan, accompanied by a fall in hepatic vascular resistance. Renal blood flow remained unchanged but renal vascular resistance fell significantly, compared with placebo, following both doses of the drug. 7. In normal man blood flow to the limb, hepatic and renal vascular beds is preserved despite dose-dependent reductions in blood pressure following single doses of flosequinan.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2015169      PMCID: PMC1368410          DOI: 10.1111/j.1365-2125.1991.tb03855.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  12 in total

Review 1.  Abnormalities in the regional circulations accompanying congestive heart failure.

Authors:  R Zelis; S H Nellis; J Longhurst; G Lee; D T Mason
Journal:  Prog Cardiovasc Dis       Date:  1975 Nov-Dec       Impact factor: 8.194

2.  Methods for the investigation of peripheral blood flow.

Authors:  A D GREENFIELD; R J WHITNEY; J F MOWBRAY
Journal:  Br Med Bull       Date:  1963-05       Impact factor: 4.291

3.  Simplified high-performance liquid chromatographic determination of flosequinan and its metabolite in plasma, serum and urine.

Authors:  M B Slegowski; C Miller; R S Porter
Journal:  J Chromatogr       Date:  1988-03-04

4.  The pharmacokinetics and haemodynamics of BTS 49 465 and its major metabolite in healthy volunteers.

Authors:  R D Wynne; E L Crampton; I D Hind
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

5.  Flosequinan in heart failure: acute haemodynamic and longer term symptomatic effects.

Authors:  A J Cowley; R D Wynne; K Stainer; L Fullwood; J M Rowley; J R Hampton
Journal:  BMJ       Date:  1988-07-16

6.  Hemodynamic effects of BTS 49465, a new long-acting systemic vasodilator drug, in patients with severe congestive heart failure.

Authors:  P D Kessler; M Packer
Journal:  Am Heart J       Date:  1987-01       Impact factor: 4.749

7.  Lignocaine and indocyanine green kinetics in patients following myocardial infarction.

Authors:  N D Bax; G T Tucker; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1980-10       Impact factor: 4.335

8.  Relationship between central hemodynamics and regional blood flow in normal subjects and in patients with congestive heart failure.

Authors:  M E Leithe; R D Margorien; J B Hermiller; D V Unverferth; C V Leier
Journal:  Circulation       Date:  1984-01       Impact factor: 29.690

9.  Cumulative hemodynamic response to short-term treatment with flosequinan (BTS 49465), a new direct-acting vasodilator drug, in severe chronic congestive heart failure.

Authors:  P D Kessler; M Packer; N Medina; M Yushak
Journal:  J Cardiovasc Pharmacol       Date:  1988-07       Impact factor: 3.105

10.  Effect of flosequinan on exercise capacity and symptoms in severe heart failure.

Authors:  J S Elborn; C F Stanford; D P Nicholls
Journal:  Br Heart J       Date:  1989-04
View more
  1 in total

1.  Flosequinan does not affect systemic and regional vascular responses to simulated orthostatic stress in healthy volunteers.

Authors:  J Duranteau; E Pussard; A Edouard; K Samii; A Berdeaux; J F Giudicelli
Journal:  Br J Clin Pharmacol       Date:  1992-09       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.